The EU regulator said Monday that laboratory studies suggest the combination vaccine - which targets both the original COVID-19 virus as well as the omicron subvariants BA.4 and BA.5 - should trigger an effective immune response. The vaccine is expected to be as safe as the original version, but the agency will continue to track its rollout globally since the data is limited.from International-News-Economic Times https://ift.tt/g6byA1C
0 comments:
Post a Comment